PURPOSE: To assess the prevalence and severity of neurocognitive impairment in adult survivors of pediatric CNS tumors and to examine associated treatment exposures. PATIENTS AND METHODS: Participants included 224 survivors of CNS tumors who were treated at St Jude Children's Research Hospital (current median age [range], 26 years [19 to 53 years]; time from diagnosis, 18 years [11 to 42 years]) and completed neurocognitive testing. Information on cranial radiation therapy (CRT) doses and parameters of delivery were abstracted from medical records. The prevalence of severe impairment (ie, at least two standard deviations below normative mean) was compared across radiation treatment groups (no CRT, focal irradiation, craniospinal irradiation) using the χ(2) test. Log-binomial models were used to estimate risk ratios (RRs) and corresponding 95% CIs for severe impairment. RESULTS: In multivariable models, craniospinal irradiation was associated with a 1.5- to threefold increased risk of severe impairment compared with no CRT (eg, intelligence: RR = 2.70; 95% CI, 1.37 to 5.34; memory: RR = 2.93; 95% CI, 1.69 to 5.08; executive function: RR = 1.74; 95% CI, 1.24 to 2.45). Seizures were associated with impaired academic performance (RR = 1.48; 95% CI, 1.02 to 2.14), attention (RR = 1.54; 95% CI, 1.12 to 2.13), and memory (RR = 1.44; 95% CI, 1.04 to 1.99). Hydrocephalus with shunt placement was associated with impaired intelligence (RR = 1.78; 95% CI, 1.12 to 2.82) and memory (RR = 1.42; 95% CI, 1.03 to 1.95). Differential follow-up time contributed to variability in prevalence estimates between survivors treated with older nonconformal and those treated with more contemporary conformal radiation therapy methods. Neurocognitive impairment was significantly associated with lower educational attainment, unemployment, and nonindependent living. CONCLUSION: Survivors of pediatric CNS tumors are at risk of severe neurocognitive impairment in adulthood. The prevalence of severe impairment is greater than expected in the general population, even in the absence of CRT, and is associated with disrupted attainment of adult social milestones.
PURPOSE: To assess the prevalence and severity of neurocognitive impairment in adult survivors of pediatric CNS tumors and to examine associated treatment exposures. PATIENTS AND METHODS: Participants included 224 survivors of CNS tumors who were treated at St Jude Children's Research Hospital (current median age [range], 26 years [19 to 53 years]; time from diagnosis, 18 years [11 to 42 years]) and completed neurocognitive testing. Information on cranial radiation therapy (CRT) doses and parameters of delivery were abstracted from medical records. The prevalence of severe impairment (ie, at least two standard deviations below normative mean) was compared across radiation treatment groups (no CRT, focal irradiation, craniospinal irradiation) using the χ(2) test. Log-binomial models were used to estimate risk ratios (RRs) and corresponding 95% CIs for severe impairment. RESULTS: In multivariable models, craniospinal irradiation was associated with a 1.5- to threefold increased risk of severe impairment compared with no CRT (eg, intelligence: RR = 2.70; 95% CI, 1.37 to 5.34; memory: RR = 2.93; 95% CI, 1.69 to 5.08; executive function: RR = 1.74; 95% CI, 1.24 to 2.45). Seizures were associated with impaired academic performance (RR = 1.48; 95% CI, 1.02 to 2.14), attention (RR = 1.54; 95% CI, 1.12 to 2.13), and memory (RR = 1.44; 95% CI, 1.04 to 1.99). Hydrocephalus with shunt placement was associated with impaired intelligence (RR = 1.78; 95% CI, 1.12 to 2.82) and memory (RR = 1.42; 95% CI, 1.03 to 1.95). Differential follow-up time contributed to variability in prevalence estimates between survivors treated with older nonconformal and those treated with more contemporary conformal radiation therapy methods. Neurocognitive impairment was significantly associated with lower educational attainment, unemployment, and nonindependent living. CONCLUSION: Survivors of pediatric CNS tumors are at risk of severe neurocognitive impairment in adulthood. The prevalence of severe impairment is greater than expected in the general population, even in the absence of CRT, and is associated with disrupted attainment of adult social milestones.
Authors: Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Thomas E Merchant; Erin N Kiehna; Chenghong Li; Xiaoping Xiong; Raymond K Mulhern Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-22 Impact factor: 7.038
Authors: Tara M Brinkman; Nan Zhang; Nicole J Ullrich; Pim Brouwers; Daniel M Green; Deo Kumar Srivastava; Lonnie K Zeltzer; Marilyn Stovall; Leslie L Robison; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Robert W Butler; Donna R Copeland; Diane L Fairclough; Raymond K Mulhern; Ernest R Katz; Anne E Kazak; Robert B Noll; Sunita K Patel; Olle Jane Z Sahler Journal: J Consult Clin Psychol Date: 2008-06
Authors: Thomas E Merchant; Heather M Conklin; Shengjie Wu; Robert H Lustig; Xiaoping Xiong Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Leslie L Robison; Daniel M Green; Melissa Hudson; Anna T Meadows; Ann C Mertens; Roger J Packer; Charles A Sklar; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Cancer Date: 2005-12-01 Impact factor: 6.921
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: Tara M Brinkman; E Anne Lown; Chenghong Li; Ingrid Tonning Olsson; Jordan Gilleland Marchak; Margaret L Stuber; Stefanie Vuotto; Deokumar Srivastava; Paul C Nathan; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin R Krull Journal: Addiction Date: 2018-10-19 Impact factor: 6.526
Authors: Tara M Brinkman; Kirsten K Ness; Zhenghong Li; I-Chan Huang; Kevin R Krull; Amar Gajjar; Thomas E Merchant; James L Klosky; Robyn E Partin; Ingrid Tonning Olsson; Frederick Boop; Paul Klimo; Wassim Chemaitilly; Raja B Khan; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong Journal: J Clin Oncol Date: 2018-08-09 Impact factor: 44.544
Authors: Sunita K Patel; Leticia Miranda; Nicole Delgado; Nicolas Barreto; Anne Nolty; Natalie C Kelly; Karla Wilson; Debbie Toomey; Anna Pawlowska Journal: J Pediatr Psychol Date: 2020-09-01
Authors: Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Deborah B Crom; Kirsten K Ness; Larry R Martinez; Michelle R Hebl; Leslie L Robison; Melissa M Hudson; Tara M Brinkman Journal: J Cancer Surviv Date: 2018-03-17 Impact factor: 4.442
Authors: David K Buchbinder; Michelle A Fortier; Kathryn Osann; Justin Wilford; Violet Shen; Lilibeth Torno; Leonard S Sender; Susan K Parsons; Lari Wenzel Journal: J Pediatr Hematol Oncol Date: 2017-11 Impact factor: 1.289